The liver is a metabolism and transfer center of amino acids as well as the prime target organ of insulin. In this report, we characterized the regulation of system N/A transporter 3 (SNAT3) in the liver of dietary-restricted mice and in hepatocytes treated with serum starvation and insulin. The expression of SNAT3 was up-regulated in dietary-restricted mice. The expression of SNAT3 protein was detected on the plasma membrane of hepatocyte-like H2.35 cells with a half-life of 6 -8 h. When H2.35 cells were depleted of serum, the expression of SNAT3 was increased. An increased concentration of insulin, however, suppressed SNAT3 expression. Interestingly, the down-regulation of SNAT3 expression by insulin was blocked by the specific phosphoinositide 3-kinase inhibitor LY294002 and mammalian target of rapamycin inhibitor, but not by MAPK inhibitor PD98059, suggesting that insulin exerts its effect on SNAT3 through phosphoinositide 3-kinase-mammalian target of rapamycin signaling. Surface biotinylation assay showed an increased level of SNAT3 on the cell surface after 0.5 h of insulin treatment, although no effect was observed after 24 h of treatment. Consistently, the transport of the substrate L-histidine was increased with short, but not long, treatment by insulin in both H2.35-and SNAT3-transfected COS-7 cells. The L-histidine uptake was inhibited significantly by L-histidine followed by 2-endoamino-bicycloheptane-2-carboxylic acid and L-cysteine and to a lesser extent by L-alanine and aminoisobutyric acid, but was not inhibited by ␣-(methylamino)isobutyric acid, implying that uptake of Lhistidine in H2.35 cells is primarily mediated by system N transporters. In conclusion, differential regulation of SNAT3 by insulin and serum starvation reinforces the functional significance of this transporter in liver physiology.
Amino acid transporters play important roles in a variety of cellular processes in the liver, including uptake of nutrients, energy and chemical metabolism, detoxification, and more importantly, the deamination and urea cycle (1, 2) . Mammalian amino acid transporters identified to date belong to a variety of protein transporter families including CAT, A, N, and EAAT (3) (4) (5) . Many of the families identified thus far consist of multiple members that are expressed in a tissue-specific manner.
The members of former system A and N transport families share common sequential and functional characteristics; therefore, recently they have been reclassified as a single family, SLC38A or System N/A Transport (SNAT) 1 family (6, 7) . We have identified and characterized three members of the SNAT family, SNAT1 (formerly mNAT2), SNAT3 (formerly mNAT), and SNAT4 (formerly mNAT3 and hNAT3), which are predominantly expressed in liver, muscle, brain, or retina (8 -11) . The protein members of SNATs have been identified by our laboratory and others; human G17 and rat SN1 (12, 13) are human and rat orthologs of SNAT3; rat GlnT (14) or SA2 (15) is a rat ortholog of SNAT1, and ATA3 (16, 17) and hNAT3 (9) are rat and human orthologs of SNAT4. The members of the SNAT transporter system family mostly convey L-glutamine, L-histidine, L-asparagine, and L-alanine across cell membranes (6, 7) . Transport of glutamine and alanine is essential for control of nitrogen metabolism in the liver and muscle (2, 19) . In these organs, glutamine is a central intermediate in the detoxification of ammonia and the production of urea (20) . Alanine directly participates in the glucose-alanine cycle between the liver and muscle for glycolysis and in the removal of ammonia from muscle. In addition, we have observed a graded distribution of SNAT3 expression from the central vein to the portal tract in the liver (8) .
Previous studies have shown that activities of N/A transport systems are regulated by growth factors and hormones (including insulin in some tissues), substrate availability, cell swelling, starvation, etc. (21) (22) (23) (24) (25) . Glucagon and glucocorticoid have been reported to stimulate hepatic system N/A transport (26 -28) . In addition, the activities of system N/A transport are up-regulated in the liver during prolonged fasting and corticosteroid treatment, becoming the rate-determining factor in intrahepatic metabolic processes (22) . Although previous studies have shown that activities of system N/A transport appear to be regulated by physiological factors, the precise regulatory mechanism at the molecular level is unknown because of the lack of information regarding the identity of transporter proteins. Recent progress in molecular cloning permits the investigation of the function and regulation of these transporters in close detail. Our recent study showed that the expression and function of SNAT4 are stimulated by insulin-activated phosphoinositide 3 kinase (PI3K) signaling in hepatocyte-like cells (11) .
In this study, we report differential regulation by insulin signaling of a member of the system N transport family, SNAT3. SNAT3 was up-regulated in the liver of dietary-restricted mice and serum-starved hepatocytes. The expression of SNAT3 was down-regulated by chronic treatment of insulin in hepatocytes. This down-regulation was mediated through insulin-activated PI3K-mTOR signaling pathway. On the other hand, acute treatment by insulin within 0.5 h stimulated the surface expression of SNAT3 with a corresponding increase in substrate uptake. Competitive inhibition analysis suggested that the L-histidine uptake was primarily mediated by system N transporters. The temporal regulation of SNAT3 by insulin in the liver suggests that this transporter plays a key role in liver physiology and function. Membrane Protein Preparation and Immunoblot Analysis-Crude membrane extracts were prepared from liver samples of various aged AD and DR mice, H2.35 cells, and neuroblastoma-like N2A cells as described previously (8) . The cell lysates were centrifuged at 100,000 ϫ g at 4°C for 30 min. The membrane pellet was resuspended, and the protein concentration was determined using the Micro BCA protein reagent assay kit. 20 g of protein were loaded, separated on a 10% SDS-PAGE, and transferred to a nitrocellulose membrane. The membranes were blotted with affinity-purified antibodies against SNAT3 (1:300 dilution) and ␤-actin (1:5000). The detailed procedure for affinity purification of SNAT3 antibody was described by Gu et al. (8) . The primary antibodies were detected using secondary anti-rabbit antiserum (1:5000) for SNAT3 or anti-mouse antiserum (1:5000) for ␤-actin. These secondary antibodies were conjugated with either horseradish peroxidase or alkaline phosphatase and were detected using either a chemiluminescence reagent kit (ECL) or alkaline phosphatase colorimetric reaction, respectively. The membranes treated with ECL were exposed to X-OMAT AR films and detected by fluorography.
EXPERIMENTAL PROCEDURES

Materials-TRI
Northern Blot Analysis-Northern blots were performed as described (29) . Total RNAs were extracted from adult mice liver and H2.35 cells using TRI Reagent® according to the manufacturer's instructions. 30 g of RNA were loaded onto an agarose gel containing formaldehyde, separated through electrophoresis, and then transferred to a nylon membrane. The membrane was hybridized at 45°C for 12 h in a hybridization solution containing 50% formamide and [ 32 P]-labeled cDNA probe corresponding to nucleotides 1135-1737 of mouse Snat3 (AF159856). The probed membrane was washed in a high stringency condition of 0.1 ϫ SSC and 0.1% SDS at 63°C for 1 h.
Immunofluorescent Staining and Confocal Laser Microscopy-The immunofluorescent detection of SNAT3 was performed as described previously (30) . H2.35 cells were fixed in 2% paraformaldehyde for 30 min, incubated with blocking solution (2% normal goat serum, 0.25% Triton X-100, 2% fish skin gelatin, and 1% bovine serum albumin in PBS) for 30 min, and incubated with affinity-purified anti-SNAT3 antibody (1:300 dilution in blocking solution) at 4°C overnight. The primary antibodies were labeled for 1 h in the dark at room temperature by fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (1:500 dilution). The specimens were analyzed using a confocal laser scanning microscope (Fluoview; Olympus) with an excitation at 488 nm by an argon laser.
Radioactive Labeling of Hepatocyte Cultures and Immunoprecipitation-The cultures were rinsed three times with culture medium deficient in methionine prior to the addition of 1 ml 35 S-labeling medium (methionine-free SNAT, system N/A transporter with 5% dialyzed FBS, 20 M methionine, and 0.5 mCi of [ 35 S]methionine) for 0.5, 1.5, and 3 h. For pulse-chase experiments, the radioactive medium was removed after a 3-h pulse. The cultures were rinsed three times with complete culture medium (Dulbecco's modified Eagle's medium supplemented with 0.5 mM methionine and 10% FBS) and incubated in non-radioactive medium at different chase periods. Cell cultures were lysed and immunoprecipitated with anti-SNAT3 affinity-purified antibody (31) .
Cell Surface Biotinylation-Biotinylation of monolayer cells was performed based on a modification of the procedure described previously (32, 33) . Briefly, H2.35 cells were labeled with 1 mg/ml EZ-link TM Sulfo-NHS-LC-Biotin in PBS at 4°C for 20 min. The cells were washed three times with PBS plus 100 mM glycine to quench the biotinylation reaction, lysed, and then mixed with the same volume of monomeric avidin beads for 1 h at room temperature. The beads were washed three times with PBS, and the biotinylated proteins were eluted by boiling for 5 min in a sample loading buffer containing 1% SDS and 2% 2-mercaptoethanol.
Transport Assay-7 g of SNAT3 cDNA cloned in pcDNA3.1 vector was transiently transfected into COS-7 cells using Lipofectamine 2000. Twenty-four hours after transfection, cells were subjected to insulin treatment and transport analysis. For analysis of the uptake of Lhistidine in cells, H2.35 and COS-7 cells were treated in the presence or absence of 0.5 g/ml insulin for 0.5-24 h, followed by three rinses with uptake buffer (150 mM LiCl, 3 mM KCl, 2 mM CaCl 2 , 0.8 mM MgCl 2 , 5 mM glucose, 10 mM HEPES, pH 7.4). These cells were incubated in uptake buffer for an additional 10 min, transferred to uptake buffer containing 50 M 3 H-labeled L-histidine for 5 min, and then washed three times with cold PBS. The cells were lysed in 1 ml of lysis buffer (2% SDS in PBS), and 200 l of cell lysates were transferred to scintillation solution for measurement of the radioactivity inside the cell. A competition assay with various amino acids and substrates was conducted to determine the contribution of various amino acid transport systems to L-histidine uptake in H2.35 cells. The rate of uptake at concentrations of 50 M L-histidine was measured in the absence or presence of 5 mM ␣-(methylamino)isobutyric acid, L-alanine, AIB, Lhistidine, 2-endoamino-bicycloheptane-2-carboxylic acid, or L-cysteine for 5 min. All experiments were repeated at least three times, and the data collected are presented as Ϯ S.D.
Statistical Analysis-Dunnett and Student-Newman-Keuls multiple comparisons tests were performed using InStat software (GraphPad Prism®, San Diego, CA). The Dunnett test was used to compare the control group versus experimental groups. The Student-Newman-Keuls test was used to compare pairs of experiments. Data are presented as the mean Ϯ S.D. with more than three determinations. * in the figures indicate the degree of significant differences as compared with the controls. (*, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001).
RESULTS
Up-regulation of SNAT3 Expression in the Liver of Dietaryrestricted Mice-
We have previously shown that SNAT3 is predominately expressed in the liver (8) . The expression of SNAT3 in ad libitum-fed (AD) and dietary-restricted (DR) mice was examined by Western blots (Fig. 1, upper panel) and densitometric measurements (lower panel). There was an increase in the expression of SNAT3 in DR mice of 4 -6-and 12-monthold mice (Fig. 1, lanes 1-4) . The increase became less dramatic in 24-month-old mice (lanes 5 and 6). The results imply that increased expression of SNAT3 in DR mice could be caused by the decreased levels of certain components or factors in the plasma.
Expression of SNAT3 in Hepatocyte-like H2.35 Cells-To understand the molecular mechanism of the regulation and function of SNAT3 in the liver, we utilized mouse hepatocyte-like H2.35 cells as an in vitro model. The expression of SNAT3 in H2.35 cells in the form of mRNA and protein was detected (Fig.  2, A and B) . A 2.4-kb form of mRNA was revealed in H2.35 cells (Fig. 2A, lane 1) and in the liver (lane 2). A 60-kDa migrating protein band was detected with anti-SNAT3 antibody in H2.35 cells (Fig. 2B, lane 1) , whereas no expression of SNAT3 protein was observed in neuroblastoma-like N2A cells (Fig. 2B, lane 2) .
Immunofluorescence confocal microscopy of the cells showed that SNAT3 was localized at the plasma membrane (Fig. 2C, b) .
The protein stability and turnover of SNAT3 were determined using pulse-chase and immunoprecipitation analysis (Fig. 3) . The cumulative level of SNAT3 protein was observed after 3 h of radioactive labeling (Fig. 3, lanes 1-3) . (Fig. 4) . In comparison to the expression of the housekeeping protein ␤-actin (Fig. 4, lower panel) , serum starvation dramatically stimulated the expression of SNAT3 (upper panel, lanes 1 and 2). SNAT3 was undetectable using preimmune antibody (upper panel, lane 3) . This observation suggests that the expression of SNAT3 is down-regulated in the presence of serum.
A Decrease in the Expression of SNAT3 Induced by InsulinThe plasma levels of insulin and insulin-like growth factor in DR mice have been shown to be markedly decreased as compared with AD mice (34, 35) . The serum, according to the information provided by the manufacturer, contains 7-13 microunits/ml insulin. Treatment with insulin significantly reduced mRNA levels of SNAT3 (Fig. 5A, upper panel) with the most dramatic effect after 24 h of insulin treatment, as shown by the densitometric quantification (lower panel). Similarly, the protein levels of SNAT3 also decreased in insulin-treated H2.35 cells (Fig. 5B ). This decrease is directly associated with the concentration of insulin being applied. This effect was initiated at 6.1 ng/ml insulin (Fig. 5B, lane 3) and became more obvious in association with increased concentrations of insulin (lanes 4 -7) . A similar decrease was also observed in insulinlike growth factor-1 (IGF-1)-treated sample (lane 8). The reduction of SNAT3 expression associated with the increasing concentrations of insulin was confirmed by densitometric measurements (Fig. 5B, lower panel) . Moreover, the decrease of SNAT3 expression induced by insulin was dependent upon the treatment period (Fig. 6) . In comparison to the expression of the housekeeping protein ␤-actin, the decrease of SNAT3 ex- lane 1), 1.5 (lane 2), and 3 h (lanes 3-9) and chased for 0 (lanes 1-3 and 9 pression was consistent after 4 h of insulin treatment (Fig. 6A,  lanes 5 and 6) , becoming more profound starting at 16 h (lanes 9 and 10) and sustaining up to 80 h of treatment (lanes 23-24) . This observation was further verified by densitometric quantification (Fig. 6B) . The decrease in the amount of SNAT3 between the treatment periods of 16 -80 h was stabilized. This could imply that longer periods of the insulin treatment may not inhibit or reduce SNAT3 biosynthesis and that the existing intracellular protein pool of SNAT3 is stabilized. Together, these data show that the expression of SNAT3 is down-regulated by the chronic treatment by insulin and this down-regulation is likely to occur at the mRNA level of SNAT3.
Regulation of SNAT3 Expression by Insulin-activated PI3K-mTOR Signaling-The insulin signaling cascade consists of two major downstream pathways, the MAPK pathway and the PI3K pathway (36) . To determine which pathway is responsible for the inhibitory effect of insulin, we utilized two well characterized specific inhibitors, PD98059 for the MAPK pathway and LY294002 for the PI3K pathway (36) . The expression of Akt, a downstream effector of PI3K, and MAPK in H2.35 cells was ascertained through the immunoblots with their corresponding antibodies (Fig. 7A) . The activation of MAPK and Akt kinase exhibited through the phosphorylation on certain amino acid residues was determined using antibodies against phosphor-MAPK (pThr-202/Tyr-204) and phospho-Akt kinase (pThr-308) (Fig. 7A) . As compared with the non-treated control (Fig. 7A, lane 1 ) . A similar inhibitory effect was also observed by another Akt inhibitor, Wortmannin (data not shown). Together, these results suggest that insulin activated MAPK and PI3K signaling in H2.35 cells and that the inhibitors PD98059 and LY294002 can efficiently block the activation of each signaling pathway.
These two inhibitors, PD98059 and LY294002, were adopted to determine which downstream pathway(s) of insulin-activated signaling was involved in down-regulation of the expression of SNAT3 in H2.35 cells (Fig. 7B) . Consistent with the data shown in Figs. 5 and 6, insulin induced a decrease in SNAT3 expression (Fig. 7B, lanes 1 and 2) . This decreased expression was completely blocked by the PI3K inhibitor LY294002 (lane 3), but not by the MAPK inhibitor PD98059 (lane 4). The inhibition of insulin-induced down-regulation of SNAT3 by the PI3K inhibitor Wortmannin was also observed (data not shown). These results suggest that the insulin-induced downregulation of SNAT3 in hepatocytes is likely to be mediated through the PI3K signaling pathway.
To further confirm the effect of PI3K pathway on the downregulation of SNAT3 by insulin, H2.35 cells were treated with various concentrations of LY294002 in conjunction with insulin (Fig. 7C ). Higher concentrations of LY294002 completely attenuated the inhibitory effect of insulin on SNAT3 expression, implying the involvement of insulin-activated PI3K signaling pathway.
mTOR was recently reported to be activated by insulin-PI3K pathway, and the activated mTOR signaling is involved in metabolic activities and cell proliferation (37-39). To determine the involvement of mTOR, we treated H2.35 cells with various concentrations (10 -1000 nM) of mTOR inhibitor, rapamycin, in the absence and presence of 0.5 g/ml of insulin (Fig. 8) . The data showed that the inhibition of SNAT3 expression by insulin was attenuated by increased concentrations of rapamycin (Fig.  8A) . To further validate that rapamycin is the regulator for SNAT3 expression, H2.35 cells were treated with various concentrations of rapamycin (10 -1000 nM) (Fig. 8B) . Rapamycin stimulated the expression of SNAT3 in a dose-dependent manner. Together, the data suggest that insulin-activated downstream PI3K-mTOR pathway is likely to regulate SNAT3 expression.
Acute Treatment by Insulin Stimulated Surface Expression and Transport Activity-The cell surface expression of SNAT3 for under 0.5 h and for 24 h of insulin treatment was determined using the cell surface biotinylation approach. With comparable levels of SNAT3 protein being subjected to precipitation by avidin beads (Fig. 9A, Preload) , there was an increase of biotinylated levels of SNAT3 in association with the insulin treatment time of 0.5 h, but this increase was mostly attenuated with 24 h of treatment (Avidin beads precipitated, lanes  1-3) . Lysates of the cells without biotin treatment were applied to avidin beads to control for nonspecific binding of SNAT3. Non-biotinylated SNAT3 was not precipitated by the beads (Avidin beads precipitated, lane 4) . The flow-through samples from cells treated with 0.5 h of insulin and biotin were reapplied to avidin beads, and none of the SNAT3 was precipitated (Avidin beads precipitated, lane 5) , implying that almost all the biotinylated SNAT3 was retained by the avidin beads. The surface expression of SNAT3 corresponds to the activity of L-histidine transport. Consistently, during acute insulin treatment such as the treatment of 0.5 and 1 h, uptake of SNAT3 substrate L-histidine by H2.35 cells was significantly increased (Fig. 9B) . There was no significant increase of L-histidine uptake in the extended time periods of insulin treatment. The acute increase of L-histidine uptake was further confirmed by COS-7 cells expressing exogenous SNAT3 (Fig. 9C) . A significant increase of substrate uptake was observed after 0.5 h of insulin treatment. However, the acute increase of the transport by insulin was not affected by the inhibitors of PI3K and MAPK (data not shown), implying that both signaling pathways are unlikely to be involved. The results suggest that acute upregulation of L-histidine uptake by insulin is likely to be mediated by the increased surface expression of SNAT3.
To determine the potential contribution of various amino acid transport systems to L-histidine uptake in H2.35 cells, a competition assay in the presence of 5 mM specific substrates was performed (Fig. 9D) . The competitive substrates included ␣-(methylamino)isobutyric acid and L-alanine for system A transport, AIB for systems A and L, L-histidine for system N, (lanes 1, 3, 5, 7, 9, 11, 13, 15,  17, 19, 21, and 23) and absence (lanes 2, 4,  6, 8, 10, 12, 14, 16, 18, 20, 22, and 24) of 0.5 g/ml insulin for 1 h (lanes 1 and 2) , 2 h (lanes 3 and 4), 4 h (lanes 5 and 6), 8 h  (lanes 7 and 8), 16 h (lanes 9 and 10) , 24 h (lanes 11 and 12), 36 h (lanes 13 and 14) , 44 h (lanes 15 and 16) (lanes 23 and 24) . The immunoblots of membranes from treated cells were labeled with anti-SNAT3 or anti-␤-actin antibody. B, the SNAT3 bands from three separate Western blots were quantified using densitometry (NIH image). Control without insulin treatment versus corresponding insulin treatment: *, p Ͻ 0.05; ***, p Ͻ 0.001. The data are presented as mean Ϯ S.D. and n ϭ 3.
2-endoamino-bicycloheptane-2-carboxylic acid for system L, and L-cysteine for systems ASC and L (1). The uptake of Lhistidine was dramatically inhibited by L-histidine, followed by 2-endoamino-bicycloheptane-2-carboxylic acid and L-cysteine and to a much lesser extent by L-alanine and AIB, but was not inhibited by ␣-(methylamino)isobutyric acid. This result suggests that L-histidine uptake was primarily mediated by system N transporters and partially by system L; however, system A transport was unlikely to be involved.
DISCUSSION
In this study, we have shown that a member of the system N amino acid transport family, SNAT3, was up-regulated in the liver of dietary-restricted mice and in serum-starved hepatocytes, implying that insulin among other components is involved in the down-regulation of SNAT3. Indeed, the expression of SNAT3 mRNA and protein was down-regulated by chronic treatment by insulin in hepatocytes. This down-regulation was mediated through insulin-activated PI3K-mTOR signaling pathway. Acute treatment by insulin, on the other hand, stimulates the migration and surface expression of SNAT3 with a corresponding increase in substrate uptake. The acute regulation by insulin appears not to be mediated by both PI3K and MAPK signaling pathways. We observed that Lhistidine transport was primarily mediated by system N, partially by system L, but not by system A transport. The temporal regulation of SNAT3 by insulin in the liver suggests that this transporter is likely to play a key role in liver physiology and function.
The levels of insulin and insulin-like growth factor in dietary-restricted rodents and primates have been demonstrated to be markedly lower than those of ad libitum-fed controls (34, 35, 40, 41) . The up-regulation of SNAT3 observed in DR mice could be caused by depressed levels of plasma insulin or other factors. This in vivo observation is consistent with our result obtained from serum-starved hepatocytes in which SNAT3 is also similarly up-regulated. Partially consistent with our observation, a recent report shows that dietary restriction increases the expression of SIRT1 deacetylase and this increase is attenuated by insulin and IGF-1, suggesting that the systemic regulation of SIRT1 is mediated, in part, by insulin and IGF-1 (42) . This up-regulation could result from the reduced level of insulin. However, SN1 (SNAT3) mRNA is found to be unaffected by streptozotocin-induced diabetic liver (43) .
Our results for the first time show that insulin at the molecular level differentially regulates the expression and functions of a member of the SNAT (Slc38a) family. SNAT3 is specifically localized in the basolateral membranes of hepatocytes (8) . Mouse H2.35 cells have been characterized to closely mimic primary differentiated hepatocytes with the expression of typical marker proteins and enzymes (44, 45) , therefore serving as an ideal in vitro model for hepatocytes. In our earlier study, we found that the treatment with insulin up-regulated L-alanine uptake and SNAT4 expression in H2.35 cells but had no effect on cell proliferation. Moreover, this process was mediated by a PI3K-dependent signaling pathway. In contrast to SNAT4, we have shown here that the expression of SNAT3 protein is down-regulated by insulin. This down-regulation is likely to be regulated at the level of gene transcription or/and the stability of mRNA because SNAT3 mRNA levels are also reduced after 24 h of insulin treatment. The decrease of SNAT3 is mediated via PI3K-mTOR signaling pathway. Conversely, acute treatment by insulin promotes surface expression of SNAT3, in conjunction with an increase in the transport activity of Lhistidine. Taken together, it appears that SNAT3 and SNAT4, although co-expressed in hepatocytes, play a differential role in response to the stimulation by insulin.
Previous studies have shown that insulin signaling induces the trafficking and transport activities of system A-and N-like transporters (21, 24, 46) and that insulin-induced uptake was facilitated by the activation of PI3K (24) . A recent study by Boehmer et al. (46) shows that serum-and glucocorticoid-dependent kinase and protein kinase B, downstream effectors of PI3K signaling, are implicated in the trafficking of SNAT3 in Xenopus oocyte. This different conclusion from our observations could be caused by the different experimental systems used, because their study was conducted using the Xenopus oocyte expression system. In addition, downstream kinases were overexpressed in their study, whereas we examined the activation of endogenously expressed kinases. Another study reveals that the activation of the N-system transport in a burn injury is mediated by PI3K signaling (47) . Stimulation of system A transport by IGF-1 depends upon PI3K activation (48) . Another study reports that insulin promotes the cell surface recruitment of rat ortholog SNAT2 in skeletal muscle cells (49) . In contrast to these reports, stimulation of system A transport by amino acid starvation in cultured fibroblasts requires extracellular signal-regulated kinase 1/2 instead of PI3K activation (50) . Previous studies have implied that stimulation of system A-like substrate transport via the MAPK pathway is mediated through a slow mechanism dependent upon overall protein synthesis (51, 52) . However, we found that the expression of SNAT3 in the insulin-treated cells was instead relatively decreased. Another report shows that short treatment by insulin stimulates system N activity in muscle cells by a mechanism that is characterized by its sensitivity to inhibition by cycloheximide, indicating the involvement of specific protein biosynthesis (53) . Here, we have shown that short treatment by insulin stimulates surface expression of SNAT3 and transport activity, independent of de novo biosynthesis of SNAT3. It is likely that insulin induces the biosynthesis of certain protein(s), which in turn facilitate migration and assembly of SNAT3 to the membrane. Another insulin-activated downstream signaling pathway, mTOR, is activated by nutrient conditions such as amino acid availability; this pathway is directly involved in the control of cell metabolism, growth, and proliferation (37) (38) (39) . mTOR signaling is reported to be involved in nutrient and protein metabolism (54, 55) and in regulation of expression and activities of system A and L transport (18, 56) . However, the regulatory mechanism of amino acid transport by mTOR signaling has not been elucidated.
Therefore, it appears that employment of different signaling transduction pathways is dependent upon the types of stimulation; ERK activation is not required for insulin-induced SNAT3 expression. Based on the specific expression pattern, transport function, and regulatory mechanisms, our results suggest that temporal regulation of SNAT3 is likely to be involved in nitrogen metabolism and other physiological functions in hepatocytes, especially in physiology and pathophysiology in which the processes of gluconeogenesis and glycogen synthesis are prominent. It is our expectation that further studies will shed light on the in vivo physiological significance of differential insulin regulation of SNAT3 in the liver.
